INVESTMENT (Details Narrative) - USD ($) |
3 Months Ended | |||
---|---|---|---|---|
Mar. 12, 2021 |
Mar. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2018 |
|
Equity Method Goodwill | $ 5,000,000 | |||
Aggregate investment | 6,000,000 | |||
Equity investment | 3,440,000 | $ 3,650,000 | ||
Convertible note investment | 1,000,000 | |||
ILiAD [Member] | ||||
Advisory and legal expenses | $ 41,000 | |||
Equity investment - net loss | $ (210,000) | |||
ILiAD [Member] | Class C units [Member] | ||||
Ownership percentage fully diluted | 7.60% | |||
Ownership percentage - non fully diluted | 9.50% | |||
ILiAD [Member] | Maximum [Member] | ||||
Aggregate investment | $ 6,000,000 | |||
ILiad Biotechnologies LLC [Member] | ||||
Maximum convertible debt offering | $ 23,500,000 | |||
Interest rate | 6.00% | |||
Notes conversion, description | The Notes have a maturity of three years with interest accruing at 6% per annum. The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction. In the event of a change-in-control, noteholders will also have the option to have the Notes repaid except in a Qualified Offering or a stock-for-stock merger. | |||
Additional convertible note investment | $ 1,000,000 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. No definition available.
|
X | ||||||||||
- Definition The average effective interest rate during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of investments, and noncurrent assets classified as other. No definition available.
|
X | ||||||||||
- Definition The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|